Katie J. Bayfield

Katie J. Bayfield

Auto-generated profile, based on publicly available information

Katie J. Bayfield

Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in The Lancet Respiratory Medicine
Verified
Journal Article
Open access
EAEric W F W Alton
Eric W F W Alton
DADavid K Armstrong
David K Armstrong
DADeborah Ashby
Deborah Ashby
KBKatie J Bayfield
Katie J Bayfield
DBDiana Bilton
Diana Bilton
PWPaul Wolstenholme-Hogg
Paul Wolstenholme-Hogg
Lung delivery of plasmid DNA encoding the CFTR gene complexed with a cationic liposome is a potential treatment option for patients with cystic fibrosis. We aimed to assess the efficacy of non-viral CFTR gene therapy in patients with cystic fibrosis. We did this randomised, double-blind, placebo-controlled, phase 2b trial in two cystic fibrosis centres with patients recruited from 18 sites in the UK. Patients (aged ≥12 years) with a forced expiratory volume in 1 s (FEV1) of 50-90% predicted and any combination of CFTR mutations, were randomly assigned, via a computer-based randomisation system, to receive 5 mL of either nebulised pGM169/GL67A gene-liposome complex or 0.9% saline (placebo) every 28 days (plus or minus 5 days) for 1 year. Randomisation was stratified by % predicted FEV1 (<70 vs ≥70%), age (<18 vs ≥18 years), inclusion in the mechanistic substudy, and dosing site (London or Edinburgh). Participants and investigators were masked to treatment allocation. The primary endpoint was the relative change in % predicted FEV1. The primary analysis was per protocol. This trial is registered with ClinicalTrials.gov, number NCT01621867. Between June 12, 2012, and June 24, 2013, we randomly assigned 140 patients to receive placebo (n=62) or pGM169/GL67A (n=78), of whom 116 (83%) patients comprised the per-protocol population. We noted a significant, albeit modest, treatment effect in the pGM169/GL67A group versus placebo at 12 months' follow-up (3.7%, 95% CI 0.1-7.3; p=0.046). This outcome was associated with a stabilisation of lung function in the pGM169/GL67A group compared with a decline in the placebo group. We recorded no significant difference in treatment-attributable adverse events between groups. Monthly application of the pGM169/GL67A gene therapy formulation was associated with a significant, albeit modest, benefit in FEV1 compared with placebo at 1 year, indicating a stabilisation of lung function in the treatment group. Further improvements in efficacy and consistency of response to the current formulation are needed before gene therapy is suitable for clinical care; however, our findings should also encourage the rapid introduction of more potent gene transfer vectors into early phase trials. Medical Research Council/National Institute for Health Research Efficacy and Mechanism Evaluation Programme.

1 March 2014 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
LKL. Kent
L. Kent
PRP. Reix
P. Reix
JIJ.A. Innes
J.A. Innes
SZS. Zielen
S. Zielen
MBM. Le Bourgeois
M. Le Bourgeois
KBK. De Boeck
K. De Boeck
The ECFS-CTN Standardisation Committee has undertaken this review of lung clearance index as part of the group's work on evaluation of clinical endpoints with regard to their use in multicentre clinical trials in CF. The aims were 1) to review the literature on reliability, validity and responsiveness of LCI in patients with CF, 2) to gain consensus of the group on feasibility of LCI and 3) to gain consensus on answers to key questions regarding the promotion of LCI to surrogate endpoint status. It was concluded that LCI has an attractive feasibility and clinimetric properties profile and is particularly indicated for multicentre trials in young children with CF and patients with early or mild CF lung disease. This is the first article to collate the literature in this manner and support the use of LCI in clinical trials in CF.

29 April 2021 in Thorax
Verified
Journal Article
Closed access
PDF file
KBKatie J Bayfield
Katie J Bayfield
TDTonia A Douglas
Tonia A Douglas
TRTim Rosenow
Tim Rosenow
JDJane C. Davies
Jane C. Davies
SEStuart J Elborn
Stuart J Elborn
PRPaul D Robinson
Paul D Robinson
Structural and functional defects within the lungs of children with cystic fibrosis (CF) are detectable soon after birth and progress throughout preschool years often without overt clinical signs or symptoms. By school age, most children have structural changes such as bronchiectasis or gas trapping/hypoperfusion and lung function abnormalities that persist into later life. Despite improved survival, gains in forced expiratory volume in one second (FEV1) achieved across successive birth cohorts during childhood have plateaued, and rates of FEV1decline in adolescence and adulthood have not slowed. This suggests that interventions aimed at preventing lung disease should be targeted to mild disease and commence in early life. Spirometry-based classifications of ‘normal’ (FEV1≥90% predicted) and ‘mild lung disease’ (FEV170%–89% predicted) are inappropriate, given the failure of spirometry to detect significant structural or functional abnormalities shown by more sensitive imaging and lung function techniques. The state and readiness of two imaging (CT and MRI) and two functional (multiple breath washout and oscillometry) tools for the detection and monitoring of early lung disease in children and adults with CF are discussed in this article.Prospective research programmes and technological advances in these techniques mean that well-designed interventional trials in early lung disease, particularly in young children and infants, are possible. Age appropriate, randomised controlled trials are critical to determine the safety, efficacy and best use of new therapies in young children. Regulatory bodies continue to approve medications in young children based on safety data alone and extrapolation of efficacy results from older age groups. Harnessing the complementary information from structural and functional tools, with measures of inflammation and infection, will significantly advance our understanding of early CF lung disease pathophysiology and responses to therapy. Defining clinical utility for these novel techniques will require effective collaboration across multiple disciplines to address important remaining research questions. Future impact on existing management burden for patients with CF and their family must be considered, assessed and minimised.To address the possible role of these techniques in early lung disease, a meeting of international leaders and experts in the field was convened in August 2019 at the Australiasian Cystic Fibrosis Conference. The meeting entitiled ‘Shaping imaging and functional testing for early disease detection of lung disease in Cystic Fibrosis’, was attended by representatives across the range of disciplines involved in modern CF care. This document summarises the proceedings, key priorities and important research questions highlighted.

1 October 2019 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
KBKatie J. Bayfield
Katie J. Bayfield
AHAlex Horsley
Alex Horsley
EAEric Alton
Eric Alton
SISamantha Irving
Samantha Irving
ABAndrew Bush
Andrew Bush
JDJane C. Davies
Jane C. Davies
Multiple-breath washout (MBW) can be performed with different gases (sulfur hexafluoride (SF6­) and nitrogen (N2)) and different devices, all of which give discrepant results. This study aimed to confirm previously reported differences and explore factors influencing discrepant results; equipment factors or the physical properties of gases used.Methods: Healthy controls (HCs) and participants with cystic fibrosis (CF) completed MBW trials on two commercially available devices (Exhalyzer D (N2) and Innocor (SF6)). Simultaneous washout of both gases at the same time on the commercial equipment and simultaneous washouts using a respiratory mass spectrometer (RMS) were completed in subsets. Primary outcomes were lung clearance index (LCI), breath number and time required to washout.Results: Breath number was higher with N2washout than SF6in both HCs and patients with CF, whether washouts were completed individually or simultaneously. The difference was greater in more advanced disease, largely caused by differences in the final part of the washout. Results from commercial devices were similar to those obtained with the RMS.Conclusions: N2MBW results were higher than SF6MBW, with some of the largest differences reported to date being observed. The biggest impact was at the end of the washout and this was even the case when gases were washed out simultaneously. N2and SF6MBW results are inherently different and should be considered as independent measurements.

6 July 2023 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
KBKatie J. Bayfield
Katie J. Bayfield
OWOliver Weinheimer
Oliver Weinheimer
CBChristie Boyton
Christie Boyton
RFRachel Fitzpatrick
Rachel Fitzpatrick
AMAnna Middleton
Anna Middleton
PRPaul D Robinson
Paul D Robinson
Optimal characterisation of early structural abnormalities has been highlighted as critical to future efforts to detect and prevent cystic fibrosis (CF) lung disease progression [1]. Computed tomography (CT) is currently the gold standard, detecting structural disease at an earlier stage than radiography or lung function testing, with predictive value for subsequent progression and later forced expiratory volume in 1 s (FEV1) decline [1]. Compared to other emerging radiological modalities for early disease detection, such as magnetic resonance imaging (MRI), CT is more widely accessible and MRI at present is not able to directly quantify the extent of bronchiectasis due to its limitations in spatial resolution. Current US CF Foundation clinical guidelines state that CT should be “considered every 2–3 years, using the lowest possible radiation dose” [2]. Early lung disease is identified on CT by air trapping, increase in airway wall thickness and airway diameter, and potentially irreversible bronchiectasis [3]. Spirometer-directed CT has standardised lung volume acquisition and outlined the importance of both inspiratory and expiratory image acquisition [4]. Consensus recommendations for “low dose” CT scanning were published in 2016 [5], but radiation exposure remains a concern, given the six-fold increase in CT use and ongoing increase in cumulative radiation exposure for CF patients [6]. Imaging requires optimal structural information at the lowest possible radiation dose [5]. Given the increased vulnerability of children to ionising radiation, “low dose” CT protocols have already been incorporated in paediatric clinical trials using CT-based primary outcome measures [7], and use of ultra-low dose (ULD) CT has emerged in adult CF research and in isolated paediatric patients [6]. However, formal validation of the effects on quantitative measures of structural disease has not been performed. Low dose (LD) CT shows limitations compared to standard dose CT because of known drifts in CT lung density dependent on dose [8]. We hypothesised that ULD implementation would not detrimentally affect structural disease detection in early CF lung disease, and specifically targeted an age range to explore this where volume variation during spirometry-directed CT could be minimised between imaging modalities. Thus, the primary aims in this study were to 1) implement spirometer-directed novel ULD CT in school-aged children with CF, and 2) validate its outcomes against same-session LD CT using visual as well as fully automated quantitative CT analysis for structural airway disease.

1 May 2012 in Medicine & Science in Sports & Exercise
Verified
Journal Article
Closed access
MJMichael A. Johnson
Michael A. Johnson
DMDean E. Mills
Dean E. Mills
DBDavid M. Brown
David M. Brown
KBKatie J. Bayfield
Katie J. Bayfield
JGJavier T. Gonzalez
Javier T. Gonzalez
GSGraham R. Sharpe
Graham R. Sharpe
This study examined the effects of different pressure threshold inspiratory loads on lactate clearance and plasma acid-base balance during recovery from maximal exercise. Eight moderately trained males (V˙O(2peak) = 4.29 ± 0.46 L·min⁻¹) performed, on different days, four maximal incremental cycling tests (power started at 0 W and increased by 20 W·min⁻¹) of identical duration (exercise time during the first trial was 16.32 ± 1.12 min). During 20-min recovery, subjects either rested passively or breathed through a constant pressure threshold inspiratory load of 10 (ITL10), 15 (ITL15), or 20 (ITL20) cm H2O. Plasma lactate concentration ([La⁻]) was measured, and acid-base balance was quantified using the physicochemical approach, which describes the dependency of [H⁺] on the three independent variables: strong ion difference ([Na⁺] + [K⁺] - [Cl⁻] + [La⁻]), the total concentration of weak acids, and the partial pressure of carbon dioxide. Peak exercise responses were not significantly different between trials. During recovery, the area under the plasma [La] curve was not different between trials (pooled mean = 261 ± 60 mEq) and the [La] measured at the end of the 20-min recovery was also similar (passive recovery = 9.2 ± 3.1 mEq·L⁻¹, ITL10 = 9.3 ± 3.1 mEq·L⁻¹, ITL15 = 8.7 ± 2.8 mEq·L⁻¹, ITL20 = 8.7 ± 3.2 mEq·L⁻¹). Similarly, changes in other strong ions contributing to strong ion difference and total concentration of weak acids, partial pressure of carbon dioxide, and, therefore, [H⁺] were not different between trials. These data suggest that, in individuals of moderate endurance training status, inspiratory loading at the intensities used in the present study does not accelerate lactate clearance or modify plasma acid-base balance during recovery from maximal exercise.